-
公开(公告)号:US20230390249A1
公开(公告)日:2023-12-07
申请号:US18453431
申请日:2023-08-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: A61K31/4192 , C07D401/14 , C07D249/06 , A61K31/27 , A61K31/454 , C07D401/04
CPC classification number: A61K31/4192 , C07D401/14 , C07D249/06 , A61K31/27 , A61K31/454 , C07D401/04 , A61K31/41
Abstract: The present invention provides compounds of Formula (I):
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.-
公开(公告)号:US11697646B2
公开(公告)日:2023-07-11
申请号:US17224161
申请日:2021-04-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Peter Tai Wah Cheng , Ying Wang , Jun Shi , Shiwei Tao , Jun Li , Lawrence J. Kennedy , Robert F. Kaltenbach, III , Hao Zhang , James R. Corte
IPC: C07D401/04 , C07D403/04 , C07D249/06 , A61P35/00 , A61P1/16 , A61P19/10 , A61P13/12 , A61P11/00 , C07C249/06 , C07C403/04
CPC classification number: C07D401/04 , A61P35/00 , C07C249/06 , C07C403/04 , C07D249/06 , C07D403/04 , A61P1/16 , A61P11/00 , A61P13/12 , A61P19/10
Abstract: The present invention provides compounds of Formula (I):
or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.-
公开(公告)号:US20200317662A1
公开(公告)日:2020-10-08
申请号:US16954556
申请日:2018-12-18
Applicant: Bristol-Myers Squibb Company
Inventor: Peter Tai Wah Cheng , Yan Shi , Hao Zhang
IPC: C07D417/14 , C07D413/14
Abstract: The present invention provides compounds of Formula (Ia) or (Ib):Formula (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US20190185446A1
公开(公告)日:2019-06-20
申请号:US16223169
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: YAN SHI , Peter Tai Wah Cheng , Ying Wang , Jun Shi , Shiwei Tao , Jun Li , Lawrence J. Kennedy , Robert F. Kaltenbach, III , Hao Zhang , James R. Corte
IPC: C07D401/04 , C07D403/04 , C07D249/06
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US20170360759A1
公开(公告)日:2017-12-21
申请号:US15628104
申请日:2017-06-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun LI , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: A61K31/4192 , A61K31/27 , C07D401/04 , A61K31/454 , C07C62/10 , A61K31/41
CPC classification number: A61K31/4192 , A61K31/27 , A61K31/41 , A61K31/454 , C07C62/10 , C07D249/06 , C07D401/04 , C07D401/14
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US20160016880A1
公开(公告)日:2016-01-21
申请号:US14774289
申请日:2014-03-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Peter T.W. Cheng , Ying Wang , Shung C. Wu , Hao Zhang
IPC: C07C59/13 , A61K31/415 , A61K31/192 , C07D307/79 , A61K31/343 , C07D333/56 , A61K31/381 , C07D271/06 , A61K31/4245 , C07C59/215 , C07C323/19 , C07C205/34 , C07D333/28 , C07D239/38 , A61K31/505 , C07D205/04 , A61K31/397 , A61K45/06 , C07D231/12
CPC classification number: C07C59/13 , A61K31/192 , A61K31/343 , A61K31/381 , A61K31/397 , A61K31/415 , A61K31/4245 , A61K31/505 , A61K45/06 , C07C43/192 , C07C43/196 , C07C47/277 , C07C59/215 , C07C59/72 , C07C62/34 , C07C69/675 , C07C69/708 , C07C69/732 , C07C69/734 , C07C69/736 , C07C69/757 , C07C69/76 , C07C205/34 , C07C235/26 , C07C237/22 , C07C311/51 , C07C323/19 , C07C2601/02 , C07C2602/08 , C07C2602/42 , C07D205/04 , C07D231/12 , C07D239/38 , C07D271/06 , C07D307/79 , C07D333/16 , C07D333/28 , C07D333/56
Abstract: The present invention provides compounds of Formula (I): (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
Abstract translation: 本发明提供式(I)的化合物:(I)或其立体异构体或其药学上可接受的盐,其中所有变量如本文所定义。 这些化合物是可用作药物的GPR120G蛋白偶联受体调节剂。
-
公开(公告)号:US08962660B2
公开(公告)日:2015-02-24
申请号:US14205421
申请日:2014-03-12
Applicant: Bristol-Myers Squibb Company
Inventor: Hao Zhang , Peter T. W. Cheng , Sean Chen , Shiwei Tao , Shung C. Wu , Lidet A Negash
IPC: A61K45/06 , A61K31/4433 , A61K31/427 , A61K31/4245 , A61K31/4196 , C07D493/08 , A61K31/35
CPC classification number: C07D493/08 , A61K31/35 , A61K31/352 , A61K31/4196 , A61K31/4245 , A61K31/427 , A61K31/4433 , A61K45/06 , A61K2300/00
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
Abstract translation: 本发明提供式(I)化合物或其立体异构体或其药学上可接受的盐,其中所有变量如本文所定义。 这些化合物是可用作药物的GPR120G蛋白偶联受体调节剂。
-
公开(公告)号:US20250057815A1
公开(公告)日:2025-02-20
申请号:US18822597
申请日:2024-09-03
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: A61K31/4192 , A61K31/27 , A61K31/41 , A61K31/454 , C07C62/10 , C07D249/06 , C07D401/04 , C07D401/14
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US11352345B2
公开(公告)日:2022-06-07
申请号:US16954320
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Peter Tai Wah Cheng , Hao Zhang , Jun Li , Tianan Fang , James R. Corte
IPC: C07D403/14 , C07D413/14 , C07D417/14
Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US11261174B2
公开(公告)日:2022-03-01
申请号:US16954221
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Peter Tai Wah Cheng , Jun Li , Yan Shi , Ying Wang , Hao Zhang , Lawrence J. Kennedy , Steven J. Walker , Ramesh Babu Reddigunta
IPC: C07D231/12 , C07D401/04 , C07D403/04 , A61K31/415 , A61K31/4427 , A61K31/496 , A61P43/00 , A61P17/02 , A61P35/00
Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
-
-
-
-
-
-
-
-